Last price
US$ 257,12
▲ 0,83% on 11/09/2026
Fundamentals
Indicators
P/L
108,46
Relação entre o preço da ação e o lucro por ação (LPA) informado pela fonte de dados.
checkhide
- Source:
- Financial Modeling Prep
- Collected:
- 14/09/2026 · 08:18
- Calculation:
- P/L = Preço da ação ÷ Lucro por Ação (LPA) No Lume Educa, o P/L vem PRONTO da fonte de dados de mercado — o sistema NÃO calcula essa divisão por conta própria a partir do preço e do LPA que exibe ao lado. O preço e o LPA aparecem aqui pra você poder CONFERIR a conta, não porque foram usados pra produzir o número exibido.
- Limitation:
- Compares price with reported earnings per share; moves with price daily and distorts when earnings are atypical.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
P/VP
—
Compara o preço de mercado de uma ação ou cota com o valor contábil/patrimonial por ação ou cota (VPA).
Dividend Yield
2,66%
Percentual pago em proventos nos 365 dias anteriores ao cálculo em relação ao preço usado na coleta.
checkhide
- Source:
- FMP (dividends) + price
- Reference:
- 31/12/2025
- Calculation:
- = US$ 6,83 (12-month payouts · dividend history via FMP · 4 payouts in 12 months) ÷ US$ 257,12 (price 11/09/2026 · quote source)
- Limitation:
- Last 12 months of payouts ÷ price; moves with price and payouts may not repeat.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
Income history
Recent dividends
| Type | Ex-date | Payment date | Value/share |
|---|---|---|---|
| dividendo | — | 16/11/2026 | US$ 1,73 |
| dividendo | — | 14/08/2026 | US$ 1,73 |
| dividendo | — | 15/05/2026 | US$ 1,73 |
| dividendo | — | 17/02/2026 | US$ 1,73 |
| dividendo | — | 14/11/2025 | US$ 1,64 |
| dividendo | — | 15/08/2025 | US$ 1,64 |
| dividendo | — | 15/05/2025 | US$ 1,64 |
| dividendo | — | 14/02/2025 | US$ 1,64 |
| dividendo | — | 15/11/2024 | US$ 1,55 |
Context
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.